US 11136315
CXCR2 antagonist
granted A61PA61P11/00
Quick answer
US patent 11136315 (CXCR2 antagonist) held by Medshine Discovery Inc. expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Medshine Discovery Inc.
- Grant date
- Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61P, A61P11/00